Fenretinide treatment accelerates atherosclerosis development in apoE‐deficient mice in spite of beneficial metabolic effects

BACKGROUND AND PURPOSE: Fenretinide, a synthetic retinoid derivative first investigated for cancer prevention and treatment, has been shown to ameliorate glucose tolerance, improve plasma lipid profile and reduce body fat mass. These effects, together with its ability to inhibit ceramide synthesis,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Pharmacol
Autors principals: Busnelli, Marco, Manzini, Stefano, Bonacina, Fabrizia, Soldati, Sabina, Barbieri, Silvia Stella, Amadio, Patrizia, Sandrini, Leonardo, Arnaboldi, Francesca, Donetti, Elena, Laaksonen, Reijo, Paltrinieri, Saverio, Scanziani, Eugenio, Chiesa, Giulia
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Research Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6989955/
https://ncbi.nlm.nih.gov/pubmed/31621898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14869
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars